Abstract: The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.
Type:
Grant
Filed:
February 15, 2018
Date of Patent:
February 20, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
February 20, 2024
Assignees:
Icahn School of Medicine at Mount Sinai, The University of North Carolina at Chapel Hill
Inventors:
Jian Jin, Gang Wang, Jing Liu, Xufen Yu, Dongxu Li
Abstract: Heparin compounds and synthetic heparin analogues having short acting anticoagulant activity are provided. Methods of synthesizing such heparin compounds, including chemoenzymatic pathways using sulfotransferase enzymes are provided. Methods of treating subjects in need of anticoagulant activity are provided.
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
February 20, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.
Type:
Grant
Filed:
August 3, 2018
Date of Patent:
February 20, 2024
Assignee:
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Inventors:
Nate Hathaway, Jian Jin, Kyle Butler, Anna Chiarella
Abstract: The present disclosure is concerned with substituted phenyl ethynyl pyridine carboxamide compounds, pharmaceutical compositions comprising the compounds, and methods of treating viral infections due to a Coronavirus such as, for example, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
December 21, 2022
Date of Patent:
February 20, 2024
Assignees:
Southern Research Institute, Vanderbilt University, University of North Carolina at Chapel Hill
Inventors:
Syed Kaleem Ahmed, Shilpa Dutta, John Phillip Tillotson, Corinne E. Augelli-Szafran, Ashish Kumar Pathak, Omar Moukha-Chafiq, Timothy Patrick Sheahan, Ralph S. Baric, Amy Catherine Sims, Mark R. Denison
Abstract: Disclosed herein is an adeno-associated virus (AAV) particle comprising a surface-bound peptide that enhances transduction of cells across the blood-brain barrier (BBB). Also disclosed herein is a modified AAV capsid protein comprising an insertion of a polypeptide that enhances transduction of cells across the BBB, and an AAV particle comprising the modified AAV capsid protein. Specific peptides are provided. Pharmaceutical formulations and method of administering/delivering a nucleic acid to a cell of the brain and/or central nervous system are also disclosed.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
February 20, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
Type:
Application
Filed:
August 31, 2022
Publication date:
February 15, 2024
Applicants:
GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare Company
Inventors:
Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
Abstract: The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.
Type:
Grant
Filed:
October 9, 2020
Date of Patent:
February 13, 2024
Assignees:
The University of North Carolina at Chapel Hill, The Johns Hopkins University
Inventors:
Samuel Lai, Ying-Ying Wang, Arthi Kannan, Kenetta Nunn, Durai Babu Subramani, Richard Cone, Bing Yang, Justin Mccallen
Abstract: The present invention provides methods and compositions comprising a particle comprising at least two different targeting agents that each bind a different protein receptor on a T cell surface.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
January 30, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: The present disclosure provides humanized antibodies and antigen-binding fragments thereof that specifically bind to SFRP2 and compositions comprising such humanized antibodies or antigen-binding fragments thereof. In some aspects, the humanized antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased SFRP2, such as cancer. In some aspects, the antibodies or antigen-binding fragments can be used to treat osteosarcoma.
Type:
Grant
Filed:
December 10, 2021
Date of Patent:
January 16, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
January 16, 2024
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie Kramer, Christopher Y. Poon
Abstract: Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.
Type:
Grant
Filed:
November 5, 2018
Date of Patent:
January 9, 2024
Assignees:
The University of North Carolina at Chapel Hill, The Research Foundation for the State University of New York
Abstract: This invention relates to vectors for delivery of human leukocyte antigen G to the eye and/or to cornea explants and methods of using the same for treatment and/or prevention of corneal transplant rejection and other disorders associated with an immune response and/or vascularization.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
January 9, 2024
Assignees:
The University of North Carolina at Chapel Hill, North Carolina State University
Inventors:
Matthew Louis Hirsch, Brian Christopher Gilger
Abstract: In one aspect, a method for emotion mapping where computing device can generate an emotional dyad, wherein the emotional dyad comprises two different emotion states. The emotion dyads can be displayed with a degree of separation for receiving an input on a scale from an individual. The computing device can receive an input of a first endpoint anchor and a second input anchor on the dyad scale. Next, the computing device receives input of an emotion anchor within the degree of separation. The computing device can subsequently calculate the length of separation from the first endpoint anchor and the second endpoint anchor, the length of separation being a neutral region, and lengths outside of the neutral region being emotion regions. The computing device determines a user's assessment by averaging the neutral region, the endpoint anchors, and an emotion anchor in one or more cycles.
Type:
Application
Filed:
June 30, 2023
Publication date:
January 4, 2024
Applicant:
University of North Carolina at Wilmington
Abstract: Methods and compositions of storing a biological material are described herein. In some embodiments, these methods provide one or more advantages over current methods. For example, methods described herein can be used to prepare and process biological materials for storage at elevated temperatures. In one aspect, a method of storing a biological material comprises providing a preservation composition and exposing the preservation composition to electromagnetic radiation to form an amorphous solid matrix containing the biological material. In some embodiments, the method further comprises monitoring temperature of the preservation composition during the exposure to the electromagnetic radiation.
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
December 26, 2023
Assignee:
THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE NC
Inventors:
Susan Trammell, Gloria Elliott, Madison Young
Abstract: Methods and compositions are provided for determining a pan-cancer clustering of cluster assignment (COCA) subtype of a cancer in an individual by detecting the expression level of at least one classifier biomarker selected from a group of classifier biomarkers for COCA subtypes. Also provided herein are methods and compositions for determining the response of an individual with a COCA subtype to a therapy such as immunotherapy.
Type:
Grant
Filed:
August 17, 2022
Date of Patent:
December 26, 2023
Assignees:
GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
Inventors:
Greg Mayhew, Hawazin Faruki, Myla Lai-Goldman, Charles M. Perou, Joel S. Parker
Abstract: The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.
Type:
Grant
Filed:
November 15, 2021
Date of Patent:
December 12, 2023
Assignees:
The University of North Carolina at Chapel Hill, University of Florida Research Foundation, Inc.
Inventors:
Aravind Asokan, Mavis Agbandje-McKenna, Long Ping Victor Tse, Brittney Gurda
Abstract: Recombinant Norovirus Virus-Like Particles (VLPs) formed from recombinant Norovirus VP1 proteins, and methods of their use and production are disclosed. In several embodiments, the Recombinant Norovirus VLPs can be used to generate an immune response to Norovirus VP1 protein in a subject. In additional embodiments, an effective amount of the recombinant Norovirus VLPs can be administered to a subject in a method of inhibiting a Norovirus infection.
Type:
Application
Filed:
October 14, 2021
Publication date:
November 30, 2023
Applicants:
The United States of America, as represented by the Secretary, Department of Health and Human Servic, The University of North Carolina at Chapel Hill, Board of Regents, the University of Texas System
Inventors:
Peter Kwong, Raffaello Verardi, Yaroslav Tsybovsky, Jason Gorman, Gwo-Yu Chuang, Li Ou, Lisa Lindesmith, Ralph Baric, George Georgiou, Inga Rimkute, Mario Roederer
Abstract: The present subject matter provides processes and kits for identifying the presence of waste water or human-derived pathogens, particularly those associated with the presence of human fecal matter, in surface or subsurface water sources.
Abstract: Disclosed herein are various optimized nucleic acids encoding the fukutin-related protein (FKRP). Recombinant vectors comprising the optimized nucleic acid (e.g. operatively linked to a muscle specific promoter), such as recombinant adeno-associated virus vectors, for expressing the protein (e.g. in skeletal and cardiac muscle), and therapeutic compositions contains the vectors are also disclosed. Therapeutic methods of administration of the vectors to a subject for the treatment of a subject with a dystroglycanopathy disorder (e.g., limb-girdle muscular dystrophy 2I) are also disclosed.
Type:
Application
Filed:
October 6, 2021
Publication date:
November 23, 2023
Applicants:
Asklepios BioPharmaceutical, Inc., The University of North Carolina at Chapel Hill
Inventors:
Martin K. Childers, Jorge Omar Yanez-Cuna, Juan Manuel Iglesias Gonzalez, Sinclair Cooper, Antonia Evripioti, Michael L. Roberts, Anna Tretiakova, Lester Suarez, Anh Nguyen, SiewHui Low, Xiao Xiao